VLCC promoted fat-loss and slimming treatments built on the US-FDA approved CoolSculpting procedure and machine. Its ads claimed 'Lose up to 600g and 7 cm in 1 session', 'Drop 1 size in 1 session permanently' and even 'Drop one size in one hour'.
India's Central Consumer Protection Authority found the claims went far beyond the approval actually granted to the machine. CoolSculpting is cleared for localised fat reduction in people with a BMI of 30 or under — not for whole-body weight loss, and not permanently.
The CCPA ruled the ads gave consumers the false impression that the treatment guaranteed permanent and significant weight loss, and directed VLCC to comply with five conditions in future ads: name the body areas it targets, state the BMI limit, disclose what the FDA did and did not clear, and make clear the procedure reduces focal fat deposits, not weight.
It fined VLCC three lakh rupees.
India's CCPA fined ₹3 lakh and imposed five conditions: name target areas, state BMI limit, disclose FDA scope, clarify it reduces focal fat, not weight.
A machine approved for one narrow job became a promise about the whole body
Turning 'reduces local fat' into 'permanent weight loss' sells hope it cannot deliver
The regulator's five conditions read like a checklist of what the ads quietly left out
A machine's approval is not a licence to enlarge its use in ads. CoolSculpting is cleared for localised fat reduction under a BMI limit — calling it permanent weight loss is an unprovable promise.
The CCPA fined VLCC ₹3 lakh for advertising CoolSculpting and Lipolaser as permanent weight-loss and size-reduction solutions, with claims like 'lose up to 600g and 7 cm in 1 session' and 'drop one size in one hour' that went beyond the US-FDA approval for focal fat reduction. It ordered VLCC to specify target body areas, state the BMI ≤ 30 requirement, disclose the FDA's inclusions and exclusions, and make clear the procedure targets focal fat deposits rather than weight loss.
FOLLOW THE EVIDENCE